Indication: Gastroesophageal Reflux Disease (GERD)

A Pharmacokinetic, Pharmacodynamic and Short-Term Safety Study of Single and Multiple Day Doses of Rabeprazole Sodium in Neonates and Pre-term Infants with a Corrected Age of Less than 44 Weeks with a Presumptive Diagnosis of GERD

Sub-indication: Gastroesophageal Reflux Disease (GERD)

Drug Study - IND

Principal Investigator: Janice Sullivan, M.D.
Norton Children's Critical Care, affiliated with the UofL School of Medicine

Sponsor: Janssen Research & Development

Search our entire site.